1. Introduction {#sec1-jcm-09-01025}
===============

Pain suppression during dental interventions has been a major accomplishment for humankind. In 1842, William E. Clarke gave ether to a patient for the removal of a tooth; later, in 1844, a dentist named Horace Wells used nitrous oxide as an anesthetic for dental extractions; and in 1846, another dentist, William T. G. Morton, became a pioneer in the use of inhaled ether as an anaesthetic at the Massachusetts General Hospital \[[@B1-jcm-09-01025]\].

Patient anxiety when facing dental procedures is determined by two circumstances: on the one hand, the prior act of anesthetizing, which in itself frequently causes a state of phobia \[[@B2-jcm-09-01025]\] and, on the other hand, the subsequent dental treatment. The number of studies on this pathology has exponentially increased over the last few years, growing from a very low number in the 1940s to the more than 6000 papers that are currently available, according to the U.S. National Library of Medicine ([Figure 1](#jcm-09-01025-f001){ref-type="fig"}).

Different therapies have been proposed for the prevention and treatment of P and DA, among them virtual reality (VR) distraction techniques \[[@B3-jcm-09-01025]\].

Although it is a concept that is difficult to define, VR is generally accepted as a three-dimensional environment generated by means of computer technology that creates a sense of immersion in the user, transporting the individual to appealing and interactive settings \[[@B4-jcm-09-01025]\].

The benefits of using VR for the reduction of dental anxiety (DA) and pain (P) levels during dental procedures has been extensively addressed in scientific literature \[[@B5-jcm-09-01025],[@B6-jcm-09-01025],[@B7-jcm-09-01025],[@B8-jcm-09-01025],[@B9-jcm-09-01025]\], and its usefulness as a distraction tool is receiving increasing attention in medical contexts \[[@B9-jcm-09-01025]\]. During aversive experiences, VR can improve pain management \[[@B10-jcm-09-01025]\] and reduce the perceived duration of the procedure \[[@B11-jcm-09-01025]\]. Moreover, a recent systematic review examined the effectiveness of virtual reality distraction in reducing pain \[[@B12-jcm-09-01025]\]. This could be an advantage for many patients who reject DA control using anti-anxiety drugs because of their disadvantages or side effects, which can be, among others, impaired cognitive function and coordination, since they act as depressants on specific areas of the central nervous system \[[@B13-jcm-09-01025],[@B14-jcm-09-01025],[@B15-jcm-09-01025]\].

The purpose of this study was to conduct a systematic review of literature comparing the effectiveness of the use of VR as a method for reducing anxiety and pain levels during dental treatment. This systematic review constitutes an essential tool to synthesize the scientific information available, increasing the validity of the conclusions and of individual studies, and identifying areas of uncertainty, where research is necessary. Meta-analysis (when possible) provides very useful information, to facilitate understanding of the effect of a treatment or intervention, both in general and in specific groups of patients. In addition, it allows us to increase the precision in the estimation of the effect, detecting effects of moderate magnitude, but of clinical importance, that could go unnoticed in primary studies.

2. Methods {#sec2-jcm-09-01025}
==========

The study selection process was carried out according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines for systematic reviews and meta-analysis \[[@B16-jcm-09-01025]\].

2.1. Protocol {#sec2dot1-jcm-09-01025}
-------------

The search strategy was conducted using the population, intervention, comparison and outcome (PICO) framework, based on the following question:

"Are distraction techniques using VR effective against the anxiety and pain caused by dental procedures?"

To answer this question, a population of patients undergoing dental treatment, with no age limit, were selected. The intervention consisted in using audio--visual or VR distraction methods. Controls were patients who were not subjected to audio--visual or VR distraction methods. The results revised in the literature were the DA or P values obtained using different validated scales: -For pain: Visual Analogic Scale (VAS), Wong--Baker Faces Scale (W--BFS) and Faces Pain Scale-Revise (FPS-R).-For anxiety: Consolability Scale (FLACC), Verbal Rating Scale (VRS), Modified Dental Anxiety Scale (MDAS), (Norman Corah's anxiety questionnaire (NCAQ) and Venham's Clinical Anxiety Rating Scale (VCARS).

2.2. Search Method for the Identification of Studies {#sec2dot2-jcm-09-01025}
----------------------------------------------------

A search of the MEDLINE, CENTRAL, PubMed, EMBASE, Wiley Library and Web of Science electronic databases was conducted in November 2019 to identify relevant scientific articles. The search terms used were: "virtual reality", "distraction systems", "dental anxiety", "pain".

2.3. Inclusion and Exclusion Criteria {#sec2dot3-jcm-09-01025}
-------------------------------------

Inclusion criteria: (a)Articles published in English.(b)Randomized controlled clinical trials related to dental anxiety and pain associated with dental procedures in children and adults.(c)Studies assessing anxiety in said procedures.

Exclusion criteria: (a)Non-randomized studies or non-controlled clinical trials.(b)Comparative studies.(c)Narrative reviews and systematic reviews.(d)Case studies.(e)Irrelevant and duplicate studies and those that did not meet the established inclusion criteria.

2.4. Data Extraction and Analysis {#sec2dot4-jcm-09-01025}
---------------------------------

Studies that made no reference to the research question were removed, and the titles and abstracts of the articles selected were obtained and entered in an Excel spreadsheet. Two reviewers (NL-V and JMF) selected the titles and abstracts independently. Discrepancies in terms of study inclusion were discussed between the two mentioned reviewers until consensus was reached. Subsequently, the full texts of the selected studies were obtained for their review and inclusion.

2.5. Risk of Bias (RoB) of Included Articles {#sec2dot5-jcm-09-01025}
--------------------------------------------

The Cochrane Collaboration, London, UK, tool was used to assess the methodology of the scientific evidence in all the selected studies \[[@B17-jcm-09-01025]\].

2.6. Quality of the Reports of the Included Studies {#sec2dot6-jcm-09-01025}
---------------------------------------------------

This was assessed according to the modified Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement \[[@B18-jcm-09-01025]\], which includes a total of 22 items. Each item was assessed by reviewers NL-V and JMF, who attributed scores of 0 (not reported) or 1 (reported), carrying out a complete count of all the studies included ([Table 1](#jcm-09-01025-t001){ref-type="table"}).

2.7. Statistical Analysis {#sec2dot7-jcm-09-01025}
-------------------------

In the meta-analysis, four studies were excluded on the grounds that two of them \[[@B7-jcm-09-01025],[@B19-jcm-09-01025]\] did not present results and the other two \[[@B20-jcm-09-01025],[@B21-jcm-09-01025]\] presented confusing results at the time of their assessment. Physiological data, such as pulse rate, degree of oxygen saturation, blood pressure and more were not included, incorporating data related to pain and anxiety only, during dental treatments. Pain and anxiety were analyzed separately in children and adults. The mean scores and SDs (standard deviations) for pain and anxiety, during the procedure with VR and control, were extracted from the selected articles, using mean scores and interquartile ranges, or reported, directly, by the authors of the studies. Other information not related to VR was not taken into consideration in our meta-analysis. The different measurement scales and VR devices used were not considered. The meta-analysis was performed using Stata v.14.2 (StataCorp LP, College Station, TX, USA) and closely followed the methods proposed by the Cochrane collaboration \[[@B17-jcm-09-01025]\]. The methods can be observed in the different tables and figures. The standardized difference of means (SMD) was used as a measure of effect to account for different measurement scales both for anxiety and pain. Statistical heterogeneity among studies was assessed using the Q test according to Dersimonian and Laird and the I2 index (heterogeneity: I2 \> 30% being moderate, \>50% substantial and \>75% considerable \[[@B17-jcm-09-01025]\]). We decided to pool the study-specific estimates with the random effects model to protect our composite estimates (for anxiety and pain) from heterogeneity in the context of a relatively limited number of studies. We also decided a priori to present the results not only for all the studies together, but also as a subgroup analysis according to age group (children and adults) derived from the different clinical usefulness and interpretation. Finally, funnel graphs (not shown) and p-value calculation (Egger test) were used to assess the publication bias.

3. Results {#sec3-jcm-09-01025}
==========

3.1. Characteristics of the Studies {#sec3dot1-jcm-09-01025}
-----------------------------------

Until November 2019, a total of 31 studies were gathered and subsequently assessed by the reviewers. Three duplicate studies were removed after an initial detection. A second detection led to the removal of 14 studies, which left a total of 14 full-text studies for the final selection \[[@B2-jcm-09-01025],[@B6-jcm-09-01025],[@B7-jcm-09-01025],[@B9-jcm-09-01025],[@B19-jcm-09-01025],[@B20-jcm-09-01025],[@B21-jcm-09-01025],[@B22-jcm-09-01025],[@B23-jcm-09-01025],[@B24-jcm-09-01025],[@B25-jcm-09-01025],[@B26-jcm-09-01025],[@B27-jcm-09-01025],[@B28-jcm-09-01025]\] ([Figure 2](#jcm-09-01025-f002){ref-type="fig"}). Pain levels were assessed in four studies, two in children \[[@B20-jcm-09-01025],[@B28-jcm-09-01025]\] and two in adults \[[@B2-jcm-09-01025],[@B21-jcm-09-01025]\]; anxiety levels in three, two in adults \[[@B9-jcm-09-01025],[@B19-jcm-09-01025]\] and one in children \[[@B26-jcm-09-01025]\]; and anxiety and pain together in seven studies, five in children \[[@B22-jcm-09-01025],[@B23-jcm-09-01025],[@B24-jcm-09-01025],[@B25-jcm-09-01025],[@B27-jcm-09-01025]\] and two in adults \[[@B6-jcm-09-01025],[@B7-jcm-09-01025]\].

[Table 2](#jcm-09-01025-t002){ref-type="table"} provides a general description of the details of each study. The risk of bias (RoB Cochrane Collaboration Tool) in the studies considered is shown in [Figure 3](#jcm-09-01025-f003){ref-type="fig"}. All the studies complied with random sequence. Two of the studies included \[[@B25-jcm-09-01025],[@B28-jcm-09-01025]\] did not comply with allocation concealment and only 35% complied with blinding of participants and personnel. It should be noted that none of the studies included complied with blinding of outcome assessment.

The STROBE criteria reported an average score of 27.4 (± 0.85), the maximum scores corresponding to the studies by Al-Halabi et al. \[[@B20-jcm-09-01025]\] and Mitrakul et al. \[[@B27-jcm-09-01025]\]. It is also noteworthy that Item 9 (Bias) was only reported in five studies \[[@B21-jcm-09-01025],[@B22-jcm-09-01025],[@B24-jcm-09-01025],[@B26-jcm-09-01025],[@B27-jcm-09-01025]\], which is also the case with Item 19 (Limitations) \[[@B20-jcm-09-01025],[@B21-jcm-09-01025],[@B22-jcm-09-01025],[@B26-jcm-09-01025],[@B27-jcm-09-01025]\] ([Table 1](#jcm-09-01025-t001){ref-type="table"}).

3.2. VR and Anxiety Management {#sec3dot2-jcm-09-01025}
------------------------------

Regarding anxiety, the composite measure is not significant, neither for all together (children + adults) (*p* = 0.302), nor for children (*p* = 0.243) ([Figure 4](#jcm-09-01025-f004){ref-type="fig"}) nor adults (*p* = 0.567) ([Figure 5](#jcm-09-01025-f005){ref-type="fig"}). The heterogeneity seems to be moderate ([Table 3](#jcm-09-01025-t003){ref-type="table"}).

3.3. VR and Pain Management {#sec3dot3-jcm-09-01025}
---------------------------

For pain, there is a significant protection for children (SMD = −0.82, i.e., a substantial effect according to Cohen's scale \[[@B29-jcm-09-01025]\]) ([Figure 6](#jcm-09-01025-f006){ref-type="fig"}), but not for adults ([Figure 7](#jcm-09-01025-f007){ref-type="fig"}), since the 95%-confidence interval (CI) includes the null value 0 ([Table 4](#jcm-09-01025-t004){ref-type="table"}). Nevertherless, it is based only on two studies.

3.4. Publication Bias and Heterogeneity {#sec3dot4-jcm-09-01025}
---------------------------------------

All estimates seem not to be affected by publication bias, according to the Egger test ([Table 1](#jcm-09-01025-t001){ref-type="table"} and [Table 2](#jcm-09-01025-t002){ref-type="table"}), but heterogeneity seems to be substantial.

4. Discussion {#sec4-jcm-09-01025}
=============

While anxiety and pain are usually associated with dental treatments, the number of studies addressing their management, especially during anesthetic block, which is one of the procedures that usually causes great anxiety among patients, is very limited \[[@B2-jcm-09-01025],[@B30-jcm-09-01025]\].

Although most studies are based on pediatric population, fear of dental treatment affects 15%--20% of the population, being recognized by the World Health Organization (WHO) as a real pathology \[[@B3-jcm-09-01025],[@B31-jcm-09-01025],[@B32-jcm-09-01025]\] that leads those who are affected by it to reject even the most basic dental treatments, such as simple dental check-ups or cleanings \[[@B33-jcm-09-01025]\]; thus, its management is essential to improve the patient's quality of life \[[@B34-jcm-09-01025]\].

Despite the existence of rigorous reviews of literature \[[@B5-jcm-09-01025]\], we believe that this is the first systematic review and meta-analysis focused on the efficacy of VR in patients, regardless of age, who suffer from anxiety triggered by dental treatments.

Our meta-analysis is based on 10 studies: two on pain, two on DA and six on DA and P together, and has proved that VR is an effective tool for reducing pain (SMD = −0.82), as reported by child patients during a variety of dental procedures.

Some studies proved that, both for pain and anxiety, the use of VR was more effective in children than in adults. A possible reason for this could be that VR is especially appealing to children, since they become more engaged in whimsical thinking and are fascinated by imaginative play \[[@B35-jcm-09-01025]\].

Nevertheless, regarding age, it should be noted that the differences in the efficacy of VR, in each study, could be due to the interpretive problems to which these analyses are susceptible; such phenomenon, known as ecological fallacies, could be associated either to the heterogeneity of the study's characteristics (methodological diversity), or to the study populations (clinical diversity) \[[@B36-jcm-09-01025]\].

VR was found to be more effective for treating P and DA than conventional treatments; however, it is difficult to assess its efficacy as compared to other types of distraction. Klassen and colleagues \[[@B37-jcm-09-01025]\] conducted a meta-analysis on distraction using music therapy as an alternative method to reduce anxiety and pain in different medical and dental procedures, finding a significant reduction, with an effect size of 0.35. A Cochrane review of psychological interventions using different types of distraction to relieve pain in children and adolescents, published in 2006 and updated in 2013 and 2018 \[[@B38-jcm-09-01025],[@B39-jcm-09-01025],[@B40-jcm-09-01025]\], reported different distraction techniques such as musical therapy, reading, watching films, hypnosis, breathing techniques and combined cognitive-behavioral strategies, as effective tools to reduce pain and anxiety during needle procedures. However, the reviewers considered the level of certainty of the review to be low, since in most of these studies there was no blinding of participants and assessors. This is consistent with our meta-analysis, according to which only 35% of the studies included met this requirement.

The heterogeneity of VR software and hardware is also relevant to the immersive approach, which is influenced by the interaction with the virtual environment, either through translation or change of position, rotation or change of direction, viewpoint or perspective and visual field. This aspect is difficult to analyze when referred to patients who are undergoing dental treatment (especially in children), since adequate patient immersion is hindered by the fact that they are expected to remain with their heads as still as possible to facilitate the professional's work \[[@B41-jcm-09-01025]\].

Large devices (hardware), also hinder the dentist's work, limiting vision of and access to the dental operation area \[[@B42-jcm-09-01025]\].

Another interesting aspect that has not been given due regard by researchers is gender difference and its significance in terms of fear of dental treatment. Patients who suffer from dental phobia are characterized by a gender-specific brain structure. Such differences have not been sufficiently addressed by researchers and clinicians, and could contribute to greater effectiveness in the management of dental phobia \[[@B43-jcm-09-01025]\].

Likewise, patients' different personality traits were not considered in the studies included, either. Patients with dental fear and a high predisposition to anxiety magnify their pain expectations when they are exposed to critical situations. When patients with dental anxiety undergo dental treatment, their beliefs about the negative consequences of bodily excitement can negatively influence their assessment of pain linked to such treatment \[[@B44-jcm-09-01025]\]. DA as a predisposing factor is associated with a state of anxiety, which has a constant impact on pain during the patient's entire dental treatment; hence, anxiety should be assessed as a critical step not only towards anxiety management in patients with high DA, but also towards P management in all dental patients \[[@B45-jcm-09-01025]\].

On the other hand, the studies included used different pain and DA assessment scales: VAS, W-BFS, FPS-R FLACC, VRS, MDAS, NCAQ and VCARS. Likewise, none of the studies included single scales for joint assessment by dentist and patient. Vital signs as emotional state indicators were also assessed in some of the studies, thus it would be convenient and appropriate to find validated scales that might be used to adequately assess all of these aspects \[[@B46-jcm-09-01025]\].

Eijlers and colleagues \[[@B5-jcm-09-01025],[@B47-jcm-09-01025]\] presented two preparatory studies for pediatric surgery based on VR training programs; however, the use of this type of preparatory program before certain dental procedures is yet to be explored by researchers and, therefore, it is currently not possible to compare effects with and without preparation.

Moreover, none of the studies drew attention to factors that could moderate VR's effectiveness, such as a subject's sensitivity to anxiety or their temperament. Shy and emotional temperaments could be associated with dental anxiety \[[@B48-jcm-09-01025],[@B49-jcm-09-01025],[@B50-jcm-09-01025],[@B51-jcm-09-01025]\].

For all these reasons, we believe that this systematic review has certain limitations in terms of number, quality and methodology of the studies included: only three studies in adults were included \[[@B2-jcm-09-01025],[@B6-jcm-09-01025],[@B9-jcm-09-01025]\], which is too scarce to consider them significant in our analysis, the authors themselves even acknowledge the limited sample size in one of them \[[@B2-jcm-09-01025]\], and the existence of major limitations with regard to participant and assessor blinding, in another \[[@B6-jcm-09-01025]\].

Hence, to determine the effects of VR on anxiety and pain in dental treatments, it would be necessary to reduce the risk of bias, to remove confusion factors and to establish a clear definition of the adequate parameters, all with the purpose of obtaining results that can be translated into broad clinical applications, so that the evidence can effectively support the practice of clinical dentistry.

5. Conclusions {#sec5-jcm-09-01025}
==============

This systematic review and meta-analysis leads to the conclusion that VR is a useful tool to reduce P in children undergoing dental treatment. No significant effect was found for DA. Studies in adults are scarce. On the other hand, most of the studies chose to focus on immersion in the pediatric population, neglecting a series of aspects that should be considered, such as training programs, the different types of software and hardware of virtual reality devices, the temperament and patient personality, gender difference and more. Due to all this, the role of virtual reality in the control of anxiety and dental pain in children and adults should be considered as a topic for future research.

Study concept and design: N.L.-V., A.L.-V., J.M.F.; Acquisition of data (Literature search and Study Selection): N.L.-V., J.F.F., J.M.R.; Analysis and interpretation of data (literature): M.B., L.F.V.J., J.H.P., L.A.B.A.; Drafting of the manuscript: N.L.-V.; A.L.-V., B.M.d.S.; Critical revision of the manuscript for important intellectual content: A.L.-V., M.B. All authors have read and agreed to the published version of the manuscript.
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jcm-09-01025-t001_Table 1

###### 

Checklist of Reporting of Observational studies in Epidemiology (STROBE) criteria reported by the included studies. Each item was judged as "0" (not reported) or "1" (reported). The total score of each of included studies was also recorded.

  Authors                         Asl Aminabadi et al. \[[@B22-jcm-09-01025]\]   Tanja-Dijkstra et al. \[[@B9-jcm-09-01025]\]   Nunna et al. \[[@B23-jcm-09-01025]\]   Gujjar et al. \[[@B6-jcm-09-01025]\]   Niharika et al. \[[@B24-jcm-09-01025]\]   Al-Halabi et al. \[[@B20-jcm-09-01025]\]   Raghav et al. \[[@B7-jcm-09-01025]\]   Tanja-Dijkstra et al. \[[@B19-jcm-09-01025]\]   Shetty et al. \[[@B25-jcm-09-01025]\]   Al-Khotani et al. \[[@B26-jcm-09-01025]\]   Mitrakul et al. \[[@B27-jcm-09-01025]\]   Asvanund et al. \[[@B28-jcm-09-01025]\]   Bentsen et al. \[[@B21-jcm-09-01025]\]   Sweta et al. \[[@B2-jcm-09-01025]\]
  ------------------------------- ---------------------------------------------- ---------------------------------------------- -------------------------------------- -------------------------------------- ----------------------------------------- ------------------------------------------ -------------------------------------- ----------------------------------------------- --------------------------------------- ------------------------------------------- ----------------------------------------- ----------------------------------------- ---------------------------------------- -------------------------------------
  Section and item                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  1\. Title and Abstract          1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  Introduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2\. Background                  1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  3\. Objectives                  1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  Methods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  4\. Study design                1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  5\. Setting                     1                                              1                                              1                                      1                                      1                                         1                                          1                                      0                                               1                                       1                                           1                                         1                                         1                                        1
  6\. Participants                1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  7\. Variables                   1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  8\. Data sources/ Measurement   1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  9\. Bias                        1                                              0                                              0                                      0                                      0                                         1                                          0                                      0                                               0                                       1                                           1                                         0                                         1                                        0
  10\. Study Size                 1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  11.Quantitative variables       1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  12\. Statistical Methods        1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  13\. Participants               1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  14\. Descriptive data           1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  15\. Outcome data               1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  16\. Main results               1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  17\. Other analyses             0                                              0                                              1                                      1                                      1                                         1                                          1                                      0                                               1                                       0                                           1                                         1                                         0                                        1
  Discussion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  18\. Key results                1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  19\. Limitations                1                                              0                                              0                                      0                                      0                                         1                                          0                                      0                                               0                                       1                                           1                                         0                                         1                                        0
  20\. Interpretation             1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  21\. Generalisability           1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  Other information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  22\. Funding                    1                                              1                                              1                                      1                                      1                                         1                                          1                                      1                                               1                                       1                                           1                                         1                                         1                                        1
  Total score                     21                                             19                                             20                                     20                                     20                                        22                                         20                                     18                                              20                                      21                                          22                                        20                                        21                                       20

Mode Value: 27.4 (± 0.85).

jcm-09-01025-t002_Table 2

###### 

Details of each study.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\                                               Journal                                        Children Values (Ma, *n*, Ar)   Adult Values (Ma, *n*, Ar)   Dental Procedure                                                                         VR Device Equipment                                                                        Measuring Scales   Outcomes   
  (Year)                                                                                                                                                                                                                                                                                                                                                                             
  ---------------------------------------------------- ---------------------------------------------- ------------------------------- ---------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------ ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Asl Aminabadi et al. 2012 \[[@B22-jcm-09-01025]\]    J Dent Res Dent Clin Dent Prospect             Ma = 5.4\                                                    Restorative treatment in primary molars.                                                 I-glasses 920HR Ilixco, Inc. Menlo Park, CA, USA.                                          MDAS               W-BFS      There was a significant decrease in pain perception and anxiety scores with the use of VR eyeglasses during dental treatment.
                                                                                                      *n* = 120\                                                                                                                                                                                                                                                                     
                                                                                                      Ar = 4--6                                                                                                                                                                                                                                                                      

  Tanja-Dijkstra et al 2014 \[[@B9-jcm-09-01025]\]     Plos One J                                                                     Ma = 33.1\                   A simulated dental treatment.                                                            Eyeglasses EVuzix iWear VR920 headset. Dual-core, 1.3GHz Intel processor with Nvidia GT\   MDAS                          Participants with higher\
                                                                                                                                      *n* = 69\                                                                                                             540 M graphics card.                                                                                                     dental anxiety showed more interested in using VR during real dental treatment than those with lower levels of dental anxiety.\
                                                                                                                                      Ar = Nr                                                                                                                                                                                                                                        Dental patients who have a positive dental treatment experience thanks to VR, might have fewer unpleasant memories and thus be less likely to postpone\
                                                                                                                                                                                                                                                                                                                                                                                     a future dental visit.

  Nunna et al 2019 \[[@B23-jcm-09-01025]\]             J Dent Anesth Pain Med                         Ma = Nr\                                                     \- Counter-stimulation.\                                                                 Lenovo smartphone, Sennheiser earphones, and ANTVR glasses.                                VCARS              W-BFS      Assessment of mean anxiety scores showed a significant difference in girls belonging to the VR group.
                                                                                                      *n* = 70\                                                    - Local anaesthesia administration with virtual reality distraction.                                                                                                                                              
                                                                                                      Ar = 7--11                                                                                                                                                                                                                                                                     

  Gujjar et al. 2019 \[[@B6-jcm-09-01025]\]            Journal of Anxiety Disorders                                                   Ma = group 1, 25.3\          Routine dental\                                                                          Eyeglasses. Dell XPS-8700 desktop with 4th Generation\                                     MDAS               VAS        The results of this study provide evidence to support the efficacy of\
                                                                                                                                      group 2, 23\                 treatment.                                                                               Intel Core i7-4790 processor (8M Cache, up to 4.0 GHz) and ASUS\                                                         VR in the treatment of dental phobia.\
                                                                                                                                      *n* = 30\                                                                                                             NVIDIA GEFORCE GTX 750 TI OC 2GB GDDR5 graphic card.                                                                     Study limitations:\
                                                                                                                                      Ar = Nr                                                                                                                                                                                                                                        - No blinding of patients or therapist in the interventions.\
                                                                                                                                                                                                                                                                                                                                                                                     - VR compared with pamphlet information.

  Niharika et al. 2018 \[[@B24-jcm-09-01025]\]         J Indian Soc Pedod Prev Dent                   Ma = Group A (7.17 ± 0.316)\                                 Routine dental care\                                                                     Google VR Box and Anti-Tank Virtual Reality 3D Glasses                                     MDAS               W-BFS      Two groups. Childhood Anxiety-Related Disorders scores did not differ significantly between the two groups.\
                                                                                                      Group B\                                                     (pulp therapy in mandibular primary molars). Local anaesthetic.                                                                                                                                                   In both groups, a statistically significant difference was detected between the two treatment sessions (with and without VR).
                                                                                                      (7.28 ± 0.300)\                                                                                                                                                                                                                                                                
                                                                                                      *n* = 40\                                                                                                                                                                                                                                                                      
                                                                                                      Ar = 4--8                                                                                                                                                                                                                                                                      

  Al-Halabi et al. 2018 \[[@B20-jcm-09-01025]\]        Anaesth Pain & Intensive Care                  Ma = 7.4\                                                    Local anaesthesia in mandibular arch (inferior alveolar nerve block).                    Eyeglasses\                                                                                                   W-BFS      Three groups. There was no significant difference in the anxiety of groups. There was a statistically significant difference in the anxiety and pain level in pulse rate.\
                                                                                                      *n* = 102\                                                                                                                                            (BlackBug™ Virtual Reality Glasses 3D VR Box\                                                                            Limitations:\
                                                                                                      Ar = 7--10                                                                                                                                            Headsets, China)                                                                                                         - No blinding of the external investigator.\
                                                                                                                                                                                                                                                                                                                                                                                     - The size of the VR Box was a little too big.

  Raghav et al. 2016 \[[@B7-jcm-09-01025]\]            BMC Oral Health J                                                              Ma = Nr\                     1\. Restorative dental procedure which may or may not be requiring local anaesthesia.\   Oculus development kit 2HMD, with a resolution of\                                         MDAS               VAS        Two groups, VR (Idle, Mirror, Syringe,\
                                                                                                                                      *n* = 30\                    2. Extraction procedure requiring local anaesthesia.                                     960 × 1080 per eye and with a 100 degree field of view.                                                                  Soundless Drill, Drill with Sound, 35- second exposures)\
                                                                                                                                      Ar = 19--45                                                                                                                                                                                                                                    and informational pamphlet control groups.\
                                                                                                                                                                                                                                                                                                                                                                                     Efficacy of VR in the\
                                                                                                                                                                                                                                                                                                                                                                                     treatment of dental phobia in the setting of the dental procedure.\
                                                                                                                                                                                                                                                                                                                                                                                     A limitation of the\
                                                                                                                                                                                                                                                                                                                                                                                     present study is the absence of in vivo exposure therapy as gold standard\
                                                                                                                                                                                                                                                                                                                                                                                     control group.

  Tanja-Dijkstra et al. 2014 \[[@B19-jcm-09-01025]\]   Trials J                                                                       Ma = Nr\                     Dental treatment                                                                         Eyeglasses.\                                                                               MDAS                          This study compared two types of VR, natural environment and urban environment.\
                                                                                                                                      *n* = 90\                                                                                                             A Sony personal 3D viewer, connected to an Alienware gaming laptop.\                                                     It included both referred patients and inhouse patients from a dental clinic and two separate procedures are described, one for each type of patient.
                                                                                                                                      Ar = Nr                                                                                                               Participants can walk around in\                                                                                         
                                                                                                                                                                                                                                                            the virtual environment by using a Zeemote JS1 thumb\                                                                    
                                                                                                                                                                                                                                                            stick controller.                                                                                                        

  Shetty et al. 2019 \[[@B25-jcm-09-01025]\]           The Journal of Clinical Paediatric Dentistry   Ma = Nr\                                                     Dental treatment\                                                                        Eyeglasses.\                                                                               MDAS               W-BFS      Two groups. The group with VR distraction, reported a decrease in the severity of anxiety.\
                                                                                                      *n* = 120\                                                   (vital pulp therapy)                                                                     VR device (i-glasses 920HR, Ilixco Inc.,\                                                                                Lower pain scores were observed in the VR group.
                                                                                                      Ar = 5--8                                                                                                                                             Menlo Park, CA, USA)                                                                                                     

  Al-Khotani et al. 2016 \[[@B26-jcm-09-01025]\]       Acta Odontologica Scandinavica                 Ma = 8.2\                                                    Dental examination, oral hygiene information, prophylaxis, restorative treatment.        Eyeglasses.\                                                                               MDAS                          Two groups. VR and control group. Significant reduction in anxiety throughout the restorative procedure (including injection with local anaesthesia) in VR group.
                                                                                                      *n* = 56\                                                                                                                                             DVD Players, gaming systems like Sony Play Station\                                                                      
                                                                                                      Ar = 7--9                                                                                                                                             Pro, Microsoft X-BOX, Nintendo WII                                                                                       

  Mitrakul et al. 2015 \[[@B27-jcm-09-01025]\]         European Journal of Paediatric Dentistry       Ma = 6.9 ± 0.9\                                              Restorative dental treatment in maxilla or mandible under local anaesthetic\             Eyeglasses. (Shenzhen Longway Vision Technology Co. Ltd, Shenzhen, China).                 FPS-R              FLACC      Two groups.\
                                                                                                      *n* = 42\                                                    Injection.                                                                                                                                                                                                        Group 1 received treatment without wearing VR\
                                                                                                      Ar = 5--8                                                                                                                                                                                                                                                                      in the first visit and wearing VR in a second visit. In Group 2, VR was used vice versa.

  Asvanund et al. 2015 \[[@B28-jcm-09-01025]\]         Quintessence International                     Ma= 7 ± 0.8\                                                 Restorative dental\                                                                      Eyeglasses (Shenzhen Longway Vision Technology\                                            FPS-R              FLACC      Two groups.\
                                                                                                      *n* = 49\                                                    treatment (local anaesthetic injection in the maxillary arch or mandibular block).       Co. Ltd, Shenzhen, China).                                                                                               The study assesses pain and anxiety without making a distinction.\
                                                                                                      Ar = 5--8                                                                                                                                                                                                                                                                      The limitation of this study is that the FLACC score was assessed by playing back the video recording of each\
                                                                                                                                                                                                                                                                                                                                                                                     visit, which was done by two paediatric dentists who could not be blinded to the child's use of VR.

  Bentsen et al. 2001 \[[@B21-jcm-09-01025]\]          Eur J of Pain- London                                                          Ma = Nr\                     Dental treatment                                                                         Video glasses\                                                                                                VAS        The study was a split-mouth, randomized design (2 dental filling). Dental treatments were performed without anaesthesia.\
                                                                                                                                      *n* = 23\                                                                                                             (NV-HD 660 PanasonicTM)                                                                                                  74% of patients would prefer VR if they were to receive a second dental filling.
                                                                                                                                      Ar = 20--49                                                                                                                                                                                                                                    

  Sweta et al. 2019 \[[@B2-jcm-09-01025]\]             Ann Maxillofac Surgery                                                         Ma = 39.72 ± 15.93.\         Local anaesthesia in patients undergoing a dental procedure.                             Nr                                                                                         NCAQ                          Local anaesthesia and extractions reported the highest anxiety levels among the patients.\
                                                                                                                                      *n* = 50\                                                                                                                                                                                                                                      Limitations of this study:\
                                                                                                                                      Ar = Nr                                                                                                                                                                                                                                        - Small sample size.\
                                                                                                                                                                                                                                                                                                                                                                                     - Patients were not in control of their VR environment.
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*n* (Participant number); Ma (Mean age years); Ar (Age range years); Nr (Not reported); VAS (Visual Analogic Scale); W--BFS (Wong--Baker Faces Scale); FPS-R (Faces Pain Scale-Revised); FLACC (Consolability Scale); VRS (Verbal Rating Scale); MDAS (Modified Dental Anxiety Scale); NCAQ (Norman Corah's anxiety questionnaire); VCARS (Venham's Clinical Anxiety Rating Scale). DA (Dental Anxiety); P (Pain).

jcm-09-01025-t003_Table 3

###### 

Meta-analysis of anxiety. Characteristics of individual studies and meta-analysis. a: Standardized difference of means.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age group/Study                                                           Year   Scale   Test   Control       SMD^a^   Heterogeneity\     Public.bias\                                                                  
                                                                                                                         I^2^ (*p*-Value)   *p*-Value (Egger Test)                                                        
  ------------------------------------------------------------------------- ------ ------- ------ ------------- -------- ------------------ ------------------------ ------- ---------------- ------- ------------------- -------------
  Children + Adults (*n* = 9)                                                              282                  284                                                  −0.54   −1.58 to 0.49    0.302   31% (*p* = 0.169)   *p* = 0.399

  Children (*n* = 7) (see [Figure 5](#jcm-09-01025-f005){ref-type="fig"})                                                                                                                                                 

  Shetty V2 \[[@B25-jcm-09-01025]\]                                         2019   MDAS    60     11.3 ± 3.5    60       16.5 ± 3.5         14.6%                    −1.48   −1.88 to −1.07                               

  Nunna M1 \[[@B23-jcm-09-01025]\]                                          2019   VCARS   35     0.57 ± 0.61   35       1.00 ± 0.84        14.5%                    −0.58   −1.06 to −0.10                               

  Niharika P1 \[[@B24-jcm-09-01025]\]                                       2018   MDAS    20     19.6 ± 0.9    20       17.3 ± 0.8         13.8%                    2.74    1.86 to 3.63                                 

  Mitrakul K2 \[[@B27-jcm-09-01025]\]                                       2015   FLACC   21     26.0 ± 9.1    21       28.0 ± 12.0        14.3%                    −0.18   −0.79 to 0.43                                

  Mitrakul K1 \[[@B27-jcm-09-01025]\]                                       2015   FLACC   21     29.5 ± 11.3   21       27.3 ± 10.6        14.3%                    0.20    −0.41 to 0.80                                

  Asl Aminabadi N1 \[[@B22-jcm-09-01025]\]                                  2012   MDAS    60     12.6 ± 1.0    60       17.7 ± 1.2         14.2%                    −4.46   −5.14 to −3.78                               

  Al-Khotani A \[[@B26-jcm-09-01025]\]                                      2016   MDAS    28     0.14 ± 0.36   28       0.75 ± 0.52        14.3%                    −1.34   −1.93 to −0.76                               

  Total                                                                                    245                  245                         100%                     −0.74   −1.99 to 0.51    0.243   38% (*p* = 0.139)   *p* = 0.536

  Adults (*n* = 2) (see [Figure 6](#jcm-09-01025-f006){ref-type="fig"})                                                                                                                                                   

  Tanja-Dijkstra K \[[@B9-jcm-09-01025]\]                                   2014   MDAS    22     3.73 ± 0.65   24       3.33 ± 0.87        54.6%                    0.51    −0.08 to 1.10                                

  Gujjar KR1 \[[@B6-jcm-09-01025]\]                                         2019   MDAS    15     18.3 ± 2.6    15       18.8 ± 2.8         45.4%                    −0.18   −0.90 to 0.54                                

  Total                                                                                    37                   39                                                   0.20    −0.48 to 0.87    0.567   0% (*p* = 0.317)    \-
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

jcm-09-01025-t004_Table 4

###### 

Meta-analysis of pain according to random effect models. Characteristics of individual studies and meta-analysis. a: Standardized difference of means.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age group/Study                                                           Year   Scale   Test   Control       SMD^a^   Heterogeneity\     Public.bias\                                                                  
                                                                                                                         I^2^ (*p*-Value)   *p*-Value (Egger Test)                                                        
  ------------------------------------------------------------------------- ------ ------- ------ ------------- -------- ------------------ ------------------------ ------- ---------------- ------- ------------------- -------------
  Children + Adults (*n* = 10)                                                             355                  355                                                  −0.77   −1.28 to −0.26   0.003   65.8% (0.002)       0.173

  Children (*n* = 8) (see [Figure 7](#jcm-09-01025-f007){ref-type="fig"})                                                                                                                                                 

  Shetty V1 \[[@B25-jcm-09-01025]\]                                         2019   W-BFS   60     2.00 ± 0.50   60       2.42 ± 1.47        13.6%                    −0.38   −0.74 to −0.0                                

  Nunna M2 \[[@B23-jcm-09-01025]\]                                          2019   W-BFS   35     3.03 ± 2.22   35       2.97 ± 2.49        13.2%                    0.03    −0.44 to 0.49                                

  Niharika P2 \[[@B24-jcm-09-01025]\]                                       2018   W-BFS   20     2.56 ± 0.39   20       5.22 ± 0.51        7.8%                     −5.71   −7.16 to −4.25                               

  Mitrakul K4 \[[@B27-jcm-09-01025]\]                                       2015   FPS-R   21     1.90 ± 2.93   21       1.90 ± 3.32        12.5%                    0.00    −0.60 to 0.60                                

  Mitrakul K3 \[[@B27-jcm-09-01025]\]                                       2015   FPS-R   21     0.86 ± 1.49   21       1.62 ± 2.94        12.5%                    −0.32   −0.93 to 0.29                                

  Asvanund Y2 \[[@B28-jcm-09-01025]\]                                       2015   FPS-R   49     2.23 ± 2.29   49       2.46 ± 3.46        13.5%                    −0.08   −0.47 to 0.32                                

  Asvanund Y1 \[[@B28-jcm-09-01025]\]                                       2015   FPS-R   49     1.57 ± 2.29   49       3.04 ± 3.08        13.5%                    −0.54   −0.94 to −0.13                               

  Asl Aminabadi N2 \[[@B22-jcm-09-01025]\]                                  2012   W-BFS   60     1.89 ± 0.65   60       3.00 ± 0.81        13.4%                    −1.50   −1.91 to −1.10                               

  Total                                                                                    315                  315                         100%                     −0.82   −1.42 to −0.22   0.008   71% (*p* = 0.001)   *p* = 0.180

  Adults (*n* = 2) (see [Figure 7](#jcm-09-01025-f007){ref-type="fig"})                                                                                                                                                   

  Sweta VR \[[@B2-jcm-09-01025]\]                                           2019   VAS     25     1.28 ± 0.89   25       2.60 ± 1.38        52.3%                    −1.12   −1.72 to −0.52                               

  Gujjar KR2 \[[@B6-jcm-09-01025]\]                                         2019   VAS     15     68 ± 10       15       70 ± 14            47.7%                    −0.18   −0.90 to 0.53                                

  Total                                                                                    40                   40                                                   −0.67   −1.58 to 0.24    0.149   0% (*p* = 0.317)    \-
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
